Pricing Log in Create free account

Enliven Therapeutics, Inc. (ELVN) vs Tarsus Pharmaceuticals, Inc. (TARS)

Enliven Therapeutics, Inc. and Tarsus Pharmaceuticals, Inc. are both Biotechnology companies. Enliven Therapeutics, Inc. and Tarsus Pharmaceuticals, Inc. are of similar size ($3.3B and $3.3B). Enliven Therapeutics, Inc. has the higher net margin (0.00% vs −102.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Enliven Therapeutics, Inc. leads on 9 and Tarsus Pharmaceuticals, Inc. on 4.

Valuation

Metric ELVN TARS Biotechnology median
P/E n/m n/m 10.26
P/S n/m 4.59 9.18
P/B 3.34 30.12 2.05
Price to free cash flow n/m 133.67 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 4.25 8.98
Earnings yield (3.69%) (22.50%) (34.89%)
Free cash flow yield (2.24%) 0.75% (24.52%)

Profitability

Metric ELVN TARS Biotechnology median
Gross margin 0.00% 93.21% 65.16%
Operating margin 0.00% (102.04%) 0.00%
Net margin 0.00% (102.93%) 0.00%
Free cash flow margin 0.00% 4.76% 0.00%
Return on equity (15.31%) (319.84%) (50.12%)
Return on assets (14.98%) (135.04%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ELVN TARS Biotechnology median
Revenue growth (TTM) — 86.34% 6.26%
EPS growth (last fiscal year) 3.17% 48.21% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ELVN TARS Biotechnology median
Debt to equity 0.00 0.70 0.00
Current ratio 64.07 1.96 4.89
Net debt to EBITDA 3.87 4.66 1.01

Dividend

Metric ELVN TARS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ELVN TARS Biotechnology median
Market cap 3.28b 3.33b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack